FMP
Aravive, Inc.
ARAV
NASDAQ
Inactive Equity
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
0.0401 USD
-0.0062 (-15.46%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
535.17k
911.51k
1.54M
1.3M
431.38k
492.64k
562.61k
642.51k
733.76k
837.97k
-
70.32
69.15
-15.95
-66.71
14.2
14.2
14.2
14.2
-15.12M
6.5M
-19.29M
-17.59M
-9.6M
-295.59k
-337.56k
-385.51k
-440.26k
-502.78k
-2.82k
712.93
-1.25k
-1.36k
-2.23k
-60
-60
-60
-60
-16.42M
5.16M
-20.48M
-18.8M
-10.72M
-295.59k
-337.56k
-385.51k
-440.26k
-502.78k
-3.07k
566.51
-1.33k
-1.45k
-2.49k
-60
-60
-60
-60
1.3M
1.33M
1.19M
1.21M
1.13M
463.61k
529.45k
604.64k
690.51k
788.58k
242.84
146.42
77.35
93.18
260.85
94.11
94.11
94.11
94.11
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)